Dell:

WHAT The team of parents, genetic and translational medicine scientists and pediatric oncologists trailblazing personalized medicine in the treatment of deadly pediatric cancers is convening in Austin to discuss the status of the worlds first personalized medicine clinical trial for pediatric cancer and plan next steps at the NMTRC Symposium 2012. Neuroblastoma affects 1 in 100,000 children and is responsible for 1 in 7 pediatric cancer deaths.

WHO Parents, advocates, oncologists from the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) and biomedical researchers from the Translational Genomics Research Institute (TGen), who are using high performance computing and cloud technology from Dell to identify targeted treatments based on the specific genetic vulnerabilities of each childs tumoran approach that could be used to treat all pediatric and adult cancers in the future.

WHY Personalized medicinetreatment based on the specific vulnerabilities of each tumor is overcoming longstanding barriers to treatment of pediatric cancer. There has been only one new treatment for pediatric cancer approved by the FDA since the 1980s, compared to 50 treatments approved for adult cancer in this same timeframe. As a result, pediatric oncologists use treatments designed for adults to treat children, with toxic side effects that are frequently as physically detrimental to the child as the cancer itself.

WHEN The following events will be available via live-stream: May 16 1-2 pm CT: Keynote: Molecular-Profiling for Optimized Precision Therapy, Dr. Timothy Triche, University of Southern California/ Childrens Hospital Los Angeles

2-4 pm CT: Panel Discussion: Kids Cloud: Access to Data Boundaries Dr. Melinda Merchant - National Cancer Institute Dr. Gary Marchant - Arizona State University Nancy Goodman - Kids V. Cancer Foundation Patrick Lacey - Friends of Will Foundation Andy Mikulak - Maxs Ring of Fire Foundation Dr. Giselle Sholler - Van Andel Institute Dr. Spyro Mousses - Translational Genomics Research Institute Dr. James Coffin - Dell

WHERE Participate and join the conversation via the #HealthCloud hashtag on Twitter. Tune in via Live-Stream here: http://www.fittotweet.com/live/nmtrc/.

See the article here:

Innovators in Pediatric Cancer to Share Progress on Ground-Breaking Personalized Medicine Clinical Trial

SAN DIEGO, May 9, 2012 /PRNewswire/ -- Sequenom, Inc. (SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that it has signed an agreement with U.S. health insurance provider Coventry Health Care National Network to provide coverage for the Sequenom Center for Molecular Medicine's (Sequenom CMM) MaterniT21 PLUS laboratory-developed test (LDT). The test detects certain fetal trisomies in women at increased risk of carrying a child with one of these chromosomal anomalies.

The agreement ensures that the 2.2 million members of the Coventry First Health PPO network will have coverage for Sequenom CMM's MaterniT21 PLUS testing service, with access to more than 5,000 hospitals and 500,000 health professionals in all 50 states, including the District of Columbia and Puerto Rico.

"The coverage of the Sequenom CMM MaterniT21 PLUS LDT by the Coventry network is an important milestone, as it will ensure that doctors who are Coventry members will have access to this important testing service to help provide expectant families with important information about their pregnancy through a noninvasive, highly accurate technology," said Harry F. Hixson, Jr., Ph.D., Chairman and CEO, Sequenom, Inc.

The MaterniT21 PLUS LDT is intended for use in pregnant women at increased risk for fetal aneuploidy and can be used as early as 10 weeks gestation. In the United States, there are an estimated 750,000 high-risk pregnancies each year. Results of the MaterniT21 PLUS LDT delivered to ordering physicians will include the presence of trisomy 21, 18 or 13 for patients at increased risk of one of these anomalies. The MaterniT21 PLUS test is available through Sequenom CMM as a testing service to physicians. To learn more, please visit Sequenomcmm.com.

About Sequenom

Sequenom, Inc. (SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

Sequenom CMM, LLC

Sequenom Center for Molecular Medicine (Sequenom CMM), a CAP accredited and CLIA-certified molecular diagnostics laboratory, is developing a broad range of laboratory-developed tests with a focus on prenatal and ophthalmic diseases and conditions. These laboratory-developed tests provide beneficial patient management options for obstetricians, geneticists, maternal fetal medicine specialists, ophthalmologists and retinal specialists. Sequenom CMM is changing the landscape in genetic disorder diagnostics using proprietary cutting edge technologies.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company's expectations and future performance under the coverage agreement with Coventry Health Care, the benefits or impact of the coverage agreement, the intended use for the MaterniT21 PLUS LDT and expectations regarding the future performance, utility, and impact of the test, the Company's commitment to improving healthcare through revolutionary genetic analysis solutions, and Sequenom CMM changing the landscape in genetic disorder diagnostics, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use by customers of new products such as the MaterniT21 PLUS LDT, reliance upon the collaborative efforts of other parties, the Company's financial position, its ability to position itself for product launches and growth and develop and commercialize new technologies and products, particularly new technologies such as noninvasive prenatal diagnostics, laboratory developed tests, and genetic analysis platforms, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, litigation involving the Company, and other risks detailed from time to time in the Company's most recently filed Quarterly Report on Form 10-Q and Annual Report on Form 10-K for the year ended December 31, 2011, and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

View original post here:

Sequenom Announces Coverage Agreement With Coventry Health Care For Sequenom Center For Molecular Medicine's ...

Public release date: 9-May-2012 [ | E-mail | Share ]

Contact: Nicole Davis ndavis@broadinstitute.org 617-714-7152 Broad Institute of MIT and Harvard

Melanoma the deadliest and most aggressive form of skin cancer has long been linked to time spent in the sun. Now a team led by scientists from the Broad Institute and Dana-Farber Cancer Institute has sequenced the whole genomes of 25 metastatic melanoma tumors, confirming the role of chronic sun exposure and revealing new genetic changes important in tumor formation.

In an article published online May 9 in Nature, the authors provide the first high-resolution view of the genomic landscape of human melanoma tumors. Previous genetic analyses have focused on the exomes of many types of cancer tumors, concentrating on the tiny fraction of the genome that provides the genetic code for producing proteins. Whole genomes contain a wealth of genetic information, and by sequencing and analyzing 25 metastatic melanoma tumors a significant technical and computational feat scientists can learn vastly more about the variety of genetic alterations that matter in melanoma.

"Sequencing the whole genome certainly adds a richness of discovery that can't be fully captured with a whole exome," said Levi A. Garraway, a senior associate member of the Broad Institute, an associate professor at Dana-Farber Cancer Institute and Harvard Medical School, and co-senior author of the paper.

"By looking across the entire genome you can more accurately determine the background mutation rate and the different classes of mutations, and more confidently describe the pattern of ultraviolet-induced mutagenesis in melanoma," said Michael F. Berger, co-first author of the paper. He worked in the Broad's cancer genome analysis group and with Garraway as a research scientist and computational biologist before moving to Memorial Sloan-Kettering Cancer Center.

When the scientists explored the whole genome data generated and analyzed at the Broad, they found that the rates of genetic mutations rose along with chronic sun exposure in patients, confirming the role of sun damage in disease development.

"Whole-genome analysis of human melanoma tumors shows for the first time the existence of many structural rearrangements in this tumor type," said Lynda Chin, a senior associate member of the Broad and co-senior author of the paper. Formerly at Dana-Farber and Harvard Medical School, she is now chair of the Department of Genomic Medicine at the University of Texas MD Anderson Cancer Center.

As expected, the scientists detected known BRAF and NRAS mutations in 24 of the 25 tumors. Both genes are involved in sending signals important in cell growth.

One other gene leaped out: PREX2, previously implicated in breast cancer for blocking a tumor-suppressor pathway, was altered in 44 percent of patients. In a larger validation cohort of 107 tumors, the frequency of the mutation was 14 percent.

View original post here:

New under the sun: Recurrent genetic mutations in melanoma

Public release date: 7-May-2012 [ | E-mail | Share ]

Contact: David Sampson ajpmedia@elsevier.com 215-239-3171 Elsevier Health Sciences

Philadelphia, PA, May 7, 2012 While active monitoring of serum prostate specific antigen (PSA) levels in men over 50 has greatly improved early detection of prostate cancer, prediction of clinical outcomes after diagnosis remains a major challenge. Researchers from the University of Pittsburgh School of Medicine have found that a genetic abnormality known as copy number variation (CNV) in prostate cancer tumors, as well as in the benign prostate tissues adjacent to the tumor and in the blood of patients with prostate cancer, can predict whether a patient will experience a relapse, and the nature of the relapse aggressive or indolent. Their report is published in the June issue of The American Journal of Pathology.

Copy number variations are large areas of the genome with either duplicated or missing sections of DNA. "Our analysis indicates that CNV occurred in both cancer and non-cancer tissues, and CNV of these tissues predicts prostate cancer progression," says lead investigator Jian-Hua Luo, MD, PhD, associate professor in the Divisions of Molecular and Cellular Pathology, and Anatomic Molecular Pathology, Department of Pathology, University of Pittsburgh School of Medicine. "Prediction models of prostate cancer relapse, or of the rate of PSA level increase after surgery, were generated from specific CNV patterns in tumor or benign prostate tissues adjacent to cancer samples."

To detect the abnormalities, scientists conducted a comprehensive genome analysis on 238 samples obtained from men undergoing radical prostatectomy: 104 prostate tumor samples, 85 blood samples from patients with prostate cancer, and 49 samples of benign prostate tissues adjacent to a tumor. A third of the samples were from patients exhibiting recurrence with a PSA level increasing at a rapid rate, doubling in less than four months (rapid increases are associated with lethal prostate cancer); a third from patients exhibiting recurrence with a PSA level increasing at a slow rate, doubling time greater than 15 months; and a third with no relapse more than five years after surgery. Three commercially available prostate cancer cell lines were also tested to validate the results.

Deletions of large segments of specific chromosomes occurred with high frequency, whereas amplification of other chromosomes occurred in only a subset of prostate cancer samples. Similar amplification and deletion of the same regions also occurred in benign prostate tissue samples adjacent to the cancer. Prostate cancer patients' blood was found to contain significant CNVs. Most were not unique and overlapped with those of prostate cancer samples.

Using gene-specific CNV from tumor, the model correctly predicted 73% of cases for relapse and 75% of cases for short PSA doubling time. The CNV model from tissue adjacent to the prostate tumor correctly predicted 67% of cases for relapse and 77% of cases for short PSA doubling time. Using median-size CNV from blood, the genome model correctly predicted 81% of the cases for relapse and 69% of the cases for short PSA doubling time.

Dr. Luo notes that there are several potential clinical applications using CNV tests. "For a patient diagnosed with prostate cancer, CNV analysis done on blood or normal tissues would eliminate the need for additional invasive procedures to decide a treatment mode. For a patient already having a radical prostatectomy, CNV analysis on the tumor or blood sample may help to decide whether additional treatment is warranted to prevent relapse. Despite some limitations, including the need for high quality genome DNA, CNV analysis on the genome of blood, normal prostate, or tumor tissues holds promise to become a more efficient and accurate way to predict the behavior of prostate cancer."

###

See original here:

Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer

Excess sun exposure, a diet rich in fish, and gene inheritance from ancient explorers and traders, are all possible theories why some dark-skinned indigenous Solomon Islanders are naturally blonde, according to new research published today in the journal Science.

The study, led by Stanford University researchers, found that 5 to 10 percent of the indigenous Solomon population have a gene that is responsible for blondeness. The trait, however, is distinctly different from the gene that causes blond hair in Europeans. Their findings reveal a genetic variant which has led the islanders to have simultaneously the darkest skin pigmentation outside of Africa and the highest prevalence of blonde hair outside of Europe.

Previous studies have proven that pigmentation is largely genetic but also has evolved to adapt to the Suns ultraviolet rays with populations near the equator having the darkest skin and hair color. However, the native Solomon Islanders differ from this trend.

This is one of the most beautiful examples to date of the mapping of a simple genetic trait in humans, David Reich, PhD, a professor of genetics at Harvard University, who was not involved in the study, said in a Stanford press release.

The research, co-led by researchers at Stanford University and Dr. Nic Timpson from the University of Bristol, sought out to find why these islanders possess such strikingly dissimilar hair and skin patterning in the world.

For the study, the team took samples from a pool of more than 1,000 Melanesian participants, 43 of which had blonde hair and 42 of which had dark hair. They carried out genetic analyses on the samples to compare their genomes. The results showed that across the whole genome, one key gene area contained the gene variation TYRP1 responsible for cell differences that produce dark pigmentation.

TYRP1 is known to influence pigmentation in humans. But the researchers found the variant of TYRP1 that causes the blonde hair in Solomon Islanders is entirely absent from the genomes in Europeans.

Here you go into an unstudied population with a small sample size and you can really find some cool things, said study coauthor Carlos Bustamante, a geneticist at Stanford Universitys School of Medicine. So what about other places, like what about light pigmentation in parts of Africa? How do we not know the genetic basis of skin and hair pigmentations across the globe?

Naturally blonde hair is a surprisingly unusual trait in humans which is typically associated with people from Scandinavian and Northern European countries, said Timpson. Our findings help explain the fascinating differences in these physical characteristics, but also underline the importance of genetic mapping using isolated populations to help shed new light on the epidemiology of disease.

Many experts believed the blonde hair of Melanesia was the result of a trait passed on by Europeans who visited the islands centuries ago.

Excerpt from:

Blondeness In Solomon Islanders Due To Genetic Variations

DUBLIN--(BUSINESS WIRE)--

Dublin - Research and Markets (http://www.researchandmarkets.com/research/vw2h92/personalized_medic) has announced the addition of the "Personalized Medicine: Companies, Trends and World Market" report to their offering.

This broad, high-level report analyzes the expanding Personalized Medicine market. This world market includes important core medical product areas that will continue to have a powerful impact on current and future healthcare delivery. This business report examines key market segments such as targeted drugs and key personalized medicine diagnostics, including companion diagnostic IVDs, LDTs, diagnostic services and related tools or technologies.

Many people already know about DNA, genes and the human genome. The science driving personalized medicine includes pharmacogenetics, pharmacoproteomics and pharmacometabalomix. Personalized medicine uses a targeted drug that depends on the patient information identified by a companion diagnostic (genetic biomarker test). The companion diagnostic identifies which patients would likely benefit from a particular therapy or those who might suffer from a bad side effect. The test information enables doctors to select the drug therapy that would benefit the patient. Drug developers in clinical trials could use a companion diagnostic to select patents that would benefit from a targeted drug.

The report discusses important technologies, including microarray, next-generation sequencing, PCR, bioinformatics, nanotechnology and other platforms. This section highlights key platforms and selected vendors. For example, the field of clinical next generation sequencing is expected to have an impact on personalized medicine.

The report covers subjects including important personalized medicine concepts. The study discusses key biomarkers, commercial diagnostics and therapeutics that drive personalized medicine. The study highlights new personalized diagnostics. This research examines the current targeted therapeutics on the market and drugs in the clinical pipeline.

The report highlights major government regulatory activities that involve personalized medicine in the US and Europe. The US FDA and the European EMA have drafted guidance papers to help drug makers and diagnostic firms develop future targeted therapies guided by companion diagnostics. The recent FDA approvals of Pfizer's Xalkori for lung cancer and Roche's Zelboraf for melanoma demonstrate that a surge in new targeted drugs is happening.

This report is in an interactive PDF format. The interactive feature uses hyperlinks that enable the reader to click the mouse to jump from Table of Contents items to sections inside the report. The hyperlinks also allow the reader to click on links to Internet information.

This study discusses important personalized medicine topics and provides the reader with key findings. The report estimates that the world personalized medicine market value will reach multi-billions of dollars in 2012, with a strong double-digit growth rate. This study reviews the activities of 31 companies.

The report uses 71 figures and tables to help the reader scan the details of major trends, market segmentation, forecast, M&As, partnerships, grant funding, patents and so on. This must-have report would benefit people with job titles including CEO, VPs, Director of Business Development, Research Directors, Entrepreneurs, Venture Capitalists, Investment Planners, Research Scientists, Consultants or Industry Analysts.

More here:

Research and Markets: Personalized Medicine: Companies, Trends and World Market

Public release date: 3-May-2012 [ | E-mail | Share ]

Contact: Rosanne Spector manishma@stanford.edu 650-725-5374 Stanford University Medical Center

STANFORD, Calif. The common occurrence of blond hair among the dark-skinned indigenous people of the Solomon Islands is due to a homegrown genetic variant distinct from the gene that leads to blond hair in Europeans, according to a new study from the Stanford University School of Medicine.

"This is one of the most beautiful examples to date of the mapping of a simple genetic trait in humans," said David Reich, PhD, a professor of genetics at Harvard University, who was not involved in the study.

The study identifying the gene responsible for blond hair in the Solomon Islands, a nation in the South Pacific, represents a rare case of simple genetics determining human appearance, and shows the importance of including understudied populations in gene mapping studies, said co-senior author Carlos D. Bustamante, PhD, professor of genetics at Stanford. The findings will be published May 4 in Science.

"Since most studies in human genetics only include participants of European descent, we may be getting a very biased view of which genes and mutations influence the traits we investigate. Here, we sought to test whether one of the most striking human traits, blond hair, had the same or different genetic underpinning in different human populations," Bustamante said.

Globally, blond hair is rare, occurring with substantial frequency only in northern Europe and in Oceania, which includes the Solomon Islands and its neighbors. "Its frequency is between 5 and 10 percent across the Solomon Islands, which is about the same as where I'm from," said co-first author Eimear Kenny, PhD, who was born in Ireland.

Many assumed the blond hair of Melanesia was the result of gene flow a trait passed on by European explorers, traders and others who visited in the preceding centuries. The islanders themselves give several possible explanations for its presence, said co-senior author Sean Myles, PhD, a former Stanford postdoctoral scholar who is now an assistant professor at the Nova Scotia Agricultural College. They generally chalked it up to sun exposure, or a diet rich in fish, he said.

After researchers at UCSF generated genetic data from the samples, Kenny, a postdoctoral scholar in Bustamante's lab, began the analysis in September 2010, the week she started at Stanford. "Within a week we had our initial result. It was such a striking signal pointing to a single gene a result you could hang your hat on. That rarely happens in science," she said. "It was one of the best experiences of my career."

In terms of genetic studies, the analysis was straightforward, said Kenny. But gathering the data, accomplished in 2009 by Myles and co-first author Nicholas Timpson, PhD, was more difficult. Much of the Solomon Islands is undeveloped, without roads, electricity or telephones. It's also one of the most linguistically diverse nations in the world, with dozens of languages spoken.

Here is the original post:

Naturally blond hair in Solomon Islanders rooted in native gene, Stanford study finds

MICHAEL FIELD/Fairfax NZ

BLOND BEAUTY: A Solomon Island boy displays his locks.

A new genetic line in blond hair has been discovered in an unlikely place - among the people of Melanesia in the Solomon Islands and Fiji.

The magazine Science reports today that scientists now realise that blond hair evolved independently at least twice in human history.

Around 10 per cent of Solomon Islanders had the blond gene, said study author Sean Myles, a geneticist at Nova Scotia Agricultural College in Truro, Canada.

Strikingly there was almost no variation in shades of blond hair.

"It looked pretty obvious to me that it was a real binary trait. You either had blond hair or you didn't," Myles told Science.

After testing 1209 Solomon Islanders scientists compared the entire genetic makeup of 43 blond and 42 dark-haired islanders.

The two groups, they found, had different versions of a crucial gene, TYRP1, one that coded for a protein involved in pigmentation. Switching one "letter" of genetic code - replacing a "C" with a "T" - meant the difference between dark hair and blond hair. A similar mutation creates blond mice by reducing the melanin content in their fur.

The gene was recessive, which meant that blonds inherited it from both parents.

View post:

New genetic line of blond hair discovered

ScienceDaily (May 3, 2012) Researchers at Seattle Children's Research Institute and their collaborators have discovered a pair of defective genes that cause a rare congenital malformation syndrome that can make it impossible for the child to breathe or eat properly without reparative surgery. In a study led by Michael L. Cunningham, MD, PhD, medical director of the Seattle Children's Hospital's Craniofacial Center, a research team pinpointed two genes known as PLCB4 and GNAI3 in a genetic pathway that affects children with auriculocondylar syndrome (ACS). ACS is a rare disorder in which a child's bottom jaw develops as an upper jaw and, in some cases, incorrectly fuses to the base of the skull.

As part of the study, the DNA of five children with similar facial features characteristic of ACS was sequenced. Cunningham and his colleague Mark J. Rieder, PhD (University of Washington) used exome sequencing, selectively sequencing those regions of the patients' DNA believed to constitute the majority of disease-causing mutations. The study, to be published in the May edition of American Journal of Human Genetics, is one of the first genomic studies to identify causative mutations in two genes for the same disorder in the same pathway in a single analysis, Dr. Cunningham said.

While children with ACS have normal cognitive development, severe cases may require an immediate tracheostomy, feeding tubes, and ultimately extensive facial reconstructive surgery to allow them to eat and breathe properly.

"Although ACS is rare, our findings suggest that these genes may also play a role in more common disorders of the jaw and ears," said Dr. Cunningham, who is also chief of the division of craniofacial medicine and professor of pediatrics in the Department of Pediatrics at the University of Washington School of Medicine. "It's possible that more common jaw problems, like the lower jaw abnormality known as Robin sequence and other skull and facial abnormalities such as craniofacial microsomia, are also caused by genes in this pathway."

ACS, a syndrome first described by scientists in 1978, is believed to affect less than one in 50,000 births, though the precise frequency is not known. It is not uncommon for the condition to be misdiagnosed or for diagnosis to be delayed. According to Dr. Cunningham it was the precision of case choice that allowed this discovery.

Of the five cases studied, two of the parents did not have this condition but were carriers for the mutation. "Now that we know the genetic pathway for ACS, we will be able to better identify and counsel people who have normal facial appearances but carry these genes, about the likelihood of passing on this mutation to their children,'' Dr. Cunningham said.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Seattle Children's.

Excerpt from:

Genetic pathway of rare facial malformation in children pinpointed

12-12-2011 11:41 Genomic Medicine Centers Meeting II December 5-6, 2011 More:

See more here:

Clinical Sequencing at Medical College of Wisconsin - Howard Jacob - Video

15-12-2011 19:02 This is a comparison of predictions between two direct-to-consumer genetics companies, 23andMe and Navigenics. This study was conducted in 2009 and published in Nature 461:725 (October 2009 issue). Authors: Pauline C. Ng, Sarah S. Murray, Samuel Levy, J. Craig Venter

See more here:

Personalized medicine: 23andMe

22-12-2011 08:22 ?For several years we have employed psychophysics, electrophysiological (ERP) and magnetic resonance imaging (MRI) techniques to study the development and plasticity of the human brain. We have studied deaf and blind individuals, people who learned their first or second spoken or signed language at different ages, and children of different ages and of different cognitive capabilities. Over the course of this research, we observed that different brain systems and related functions display markedly different degrees, or 'profiles', of neuroplasticity. Some systems appear quite strongly determined and are not altered even when experience has been very different. Other systems are highly modifiable by experience and are dependent on experience but only during particular time periods ("sensitive periods"). Series: "MIND Institute Lecture Series on Neurodevelopmental Disorders" [Health and Medicine] [Professional Medical Education] [Show ID: 23072]

Originally posted here:

Experiential Genetic and Epigenetic Effects on Neurocognitive Development - Video

30-01-2012 09:19 Website Shirts and Stuff My twitter Like Brainstorm on Facebook Technology News Medical News Biotechnology News Hosted by Contributors RNA Video

More here:

Damnit I'm A Doctor Not A TSA Agent (Brainstorm Ep43) - Video

31-01-2012 08:03 The drug Kalydeco has been approved to treat patients with one of the mutations that cause cystic fibrosis. FDA's Stephen Spielberg, MD, Ph.D, tells how this targeted treatment represents how personalized medicine will revolutionize health care.

View original post here:

Cystic Fibrosis Drug is Personalized Medicine - Video

05-02-2012 06:28 Jared Taylor, editor of American Renaissance, explains the biological basis of race. [Re-posted With Permission] Sources: Weiss, Rick, and Justin Gillis. "Teams Finish Mapping Human DNA." Washington Post 27 June 2000: A1. Print. Edwards, AWF "Human Genetic Diversity: Lewontin's Fallacy." BioEssays 25.8 (2003): 798-801. Web. Lewontin, Richard C. "The Apportionment of Human Diversity." Evolutionary Biology 6 (1972): 391-98. Print. Risch, Niel J. et al. "Genetic Structure, Self-Identified Race/Ethnicity, and Confounding in Case-Control Association Studies." American Journal of Human Genetics 76.2 (2005): 268-75. Web. Ousley, Stephen D. "Understanding Race and Human Variation: Why Forensic Anthropologists Are Good at Identifying Race." American Journal of Physical Anthropology 139 (2009): 68-76. Web. Sauer, Norman J. "Forensic Anthropology and the Concept of Race: If Races Don't Exist, Why Are Forensic Anthropologists So Good at Identifying Them?" Social Science Medicine 34.2 (1992): 107-11. Print. Norton, Cherry. "Hidden Black Ancestry Linked to Rise in Sickle Cell Blood Disorder." Independent. 23 Oct. 1999. Web. Motulsky, Arno G. "Frequency of Sickling Disorders in US Blacks." New England Journal of Medicine 288 (1973): 31-33. Print. "Hemochromatosis." PubMed Health. 12 Apr. 2010. Web. Parker, Heidi G et al. "Genetic Structure of the Purebred Domestic Dog." Science 304 ...

Read more here:

The Reality of Race - Video

12-03-2012 12:02 Plants, animals, and microbes have led to the development of treatments for many diseases including cancer, glaucoma, malaria, inflammatory disorders, high blood pressure, and many other disorders. The staggering loss of biodiversity today affects the ability of researchers to tap natural sources for medicine and exposes people to new risks from diseases like West Nile Virus and Lyme disease. Climate change, one of the drivers of biodiversity loss, also impacts children's health. Aaron Bernstein, MD, MPH, Associate Director of the Center for Health and the Global Environment at Harvard Medical School, Physician in Medicine, Children's Hospital Boston, and Instructor in Pediatrics, Harvard Medical School speaks with Link TV correspondent Miles Benson on the connections between biological diversity, medicine, and health.

Read more:

Aaron Bernstein on Biological Diversity and Medicine - Video

22-03-2012 14:15 Dr. Rebecca Carley talked about the horrors of vaccines and the deliberate depopulation intentions behind vaccination campaigns. website: (expand for more info) "The only safe vaccine is one that is never used." (Dr.James R. Shannon, former Director National Institute of Health) Vaccine Ingredients - Formaldehyde, Aspartame, Mercury + more The numbers of microbes, antibiotics, chemicals, heavy metals and animal byproducts is staggering. Would you knowingly inject these materials into your children? This following list of common vaccines and their ingredients should shock anyone Acel-Immune DTaP - Diphtheria-Tetanus-Pertussis Wyeth-Ayerst 800.934.5556 * diphtheria and tetanus toxoids and acellular pertussis adsorbed, formaldehyde, aluminum hydroxide, aluminum phosphate, thimerosal, and polysorbate 80 (Tween-80) gelatin Act HIB Haemophilus - Influenza B Connaught Laboratories 800.822.2463 * Haemophilus influenza Type B, polyribosylribitol phosphate ammonium sulfate, formalin, and sucrose Attenuvax - Measles Merck & Co., Inc. 800-672-6372 * measles live virus neomycin sorbitol hydrolized gelatin, chick embryo Biavax - Rubella Merck & Co., Inc. 800-672-6372 * rubella live virus neomycin sorbitol hydrolized gelatin, human diploid cells from aborted fetal tissue BioThrax - Anthrax Adsorbed BioPort Corporation 517.327.1500 * nonencapsulated strain of Bacillus anthracis aluminum hydroxide, benzethonium chloride, and formaldehyde DPT - Diphtheria-Tetanus-Pertussis ...

See the article here:

Dr. Rebecca Carley : Vaccines

25-03-2012 14:50 Wholistic Vocabulary - Scientific Logistics - Rationale Procedure - Metaphysics Physics -- Expansive Life Force Integration modern Chinese [ Internal ] Medicine - Complementary Therapy Developed by Dr. Julie Trudeau over the course of MORE THAN 25 years; due to The Dedicated Love of ' working smarter ' in clinical experience, observation & research, witnessing consistent cell regeneration. The CIRCULATION of the INNER (mildly magnetic) [ cerebral spinal fluid FLOW ] + Internal Medicine OILS of the pituitary gland = [ " Fountain of Youth " ] of the Cranial Sacral PUMP GENERATES...the Quantum ' ENERGETIC ' " Fountain of Youth " around it [ The Quantum ' ENERGETIC ' " Fountain of Youth " ] or the metaphysical, Human, Electro - magnetic Field is generated by the WHOLE centrifugal FORCE of the continual SPINNING of the electro - magnetic fluids of the [ ' FLUID ' " Fountain of Youth " ] in the Cranial Sacral Pump mechanism; safely & painlessly delivering the following potential Health Benefits to clients with ACTIVE health responsibility, consistently performing the suggested dietary & lifestyle changes over time. • 100% safe & Natural detox /effective fat burning while simultaneously increasing TISSUE ELASTICITY, therefore MAXIMUM NUTRIENT (food, pills [vitamins & drugs] ) ABSORPTION! • Complete cardio vascular blood supply is MAXIMISED to the whole body, including around ALL of the organs. • IMMUNE stimulation, protection from bacterial & viral attack, INTEGRATING the body's ...

Continue reading here:

C - Modern Chinese [Internal] Medicine / Expansive Life Force Integration - Video

02-04-2012 17:13 More Science Videos Shirts and Stuff Follow us on Twitter Like us on Facebook Technology News Medical News Biotechnology News Hosted by Contributors

Read the original:

Dr. Watson IBMD (Brainstorm Ep60) - Video

30-03-2012 22:06 Using genetic information to diagnose and cure disease ''Know thyself.'' / ''The burden of knowing.'' Air Date 28 March 2012 Written, produced and directed by Sarah Holt PBS NOVA WGBH Educational Foundation

View post:

Cracking Your Genetic Code - Video